Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterNo recent work listed

Aparna Balachandran

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5063250492, A5111885400. Sources: OpenAlex.

Their work

Papers
10 (first author 4, last author 1)
Trials
0
Grants
0
Labs led
1
Collaborators
30
Papers, trials and grants by year

2011: 1 paper · 2012: 5 papers · 2013: none · 2014: 1 paper · 2015: 2 papers · 2016: none · 2017: none · 2018: 1 paper

Papers 10

  1. Utility of (18) F-FDG PET/CT and CECT in conjunction with serum CA 19-9 for detecting recurrent pancreatic adenocarcinoma. First author DOI 10.1007/s00261-017-1316-z↗
  2. Quantitative and Qualitative Comparison of Single-Source Dual-Energy Computed Tomography and 120-kVp Computed Tomography for the Assessment of Pancreatic Ducta… Co-author DOI 10.1097/rct.0000000000000295↗
  3. Characterization of Anthropometric Changes that Occur During Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-014-4285-2↗
  4. Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. First author DOI 10.1111/hpb.12154↗
  5. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Last author DOI 10.1002/cncr.27636↗
  6. Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer. Co-author DOI 10.1007/s11605-011-1748-7↗
  7. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis. Co-author DOI 10.1016/j.anndiagpath.2011.08.005↗
  8. Imaging of pancreatic adenocarcinoma: update on staging/resectability. First author DOI 10.1016/j.rcl.2012.03.008↗
  9. Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therap… Co-author DOI 10.1245/s10434-011-2211-4↗
  10. Imaging in staging and management of pancreatic ductal adenocarcinoma. First author DOI 10.1007/s13193-010-0017-7↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Matthew H. G. Katz · 8 shared papers, 2012–2018 · strength 0.31
  2. Priya Bhosale · 5 shared papers, 2012–2018 · strength 0.24
  3. Jason B. Fleming · 7 shared papers, 2012–2015 · strength 0.22
  4. Gauri Rajani Varadhachary · 6 shared papers, 2012–2015 · strength 0.19
  5. Jeffrey E. Lee · 6 shared papers, 2012–2015 · strength 0.18
  6. Jean‐Nicolas Vauthey · 5 shared papers, 2012–2015 · strength 0.15
  7. Peter W. T. Pisters · 5 shared papers, 2012–2014 · strength 0.14
  8. Eric Peter Tamm · 3 shared papers, 2012–2015 · strength 0.12
  9. Robert A. Wolff · 4 shared papers, 2012–2014 · strength 0.11
  10. Christopher H. Crane · 4 shared papers, 2012–2014 · strength 0.11
  11. Huamin Wang · 4 shared papers, 2012–2014 · strength 0.11
  12. Sampanna Jung Rayamajhi · 1 shared paper, 2018 · strength 0.10
  13. David R. Fogelman · 2 shared papers, 2012–2015 · strength 0.07
  14. Ching-Wei David Tzeng · 2 shared papers, 2012–2014 · strength 0.06
  15. Ott Le · 1 shared paper, 2015 · strength 0.06
  16. E.S. Paulson · 1 shared paper, 2015 · strength 0.06
  17. Raghunandan Vikram · 1 shared paper, 2011 · strength 0.06
  18. James L. Abbruzzese · 2 shared papers, 2012 · strength 0.05
  19. An Ngo‐Huang · 1 shared paper, 2015 · strength 0.04
  20. Nathan H. Parker · 1 shared paper, 2015 · strength 0.04
  21. Maria Q. B. Petzel · 1 shared paper, 2015 · strength 0.04
  22. Claudius H. Conrad · 1 shared paper, 2015 · strength 0.04
  23. Amanda Beth Cooper · 1 shared paper, 2015 · strength 0.04
  24. Douglas B. Evans · 1 shared paper, 2015 · strength 0.04
  25. Mediha Ahmad · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.